Robert J Bitterman bought $7,446 of PHIO
Chairman, Pres & CEO at Phio Pharmaceuticals Corp.. 4,200 shares at an average of $1.77, traded May 21, 2025, filed May 23, 2025.
Score components
- +25RoleCEO
- 0Trade size$7k at market
- +6Relative to holdingsHoldings up 22%
- +8Price context73% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +29.4%, 3m +19.4%, 6m -36.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001062993-25-010155, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 21, 2025 | POpen-market purchase Common Stock, $0.0001 par value | +3,000 | $1.77 | $5,310 | 22,449 | May 23, 2025 |
| May 22, 2025 | POpen-market purchase Common Stock, $0.0001 par value | +1,200 | $1.78 | $2,136 | 23,649 | May 23, 2025 |
Related signals
Other insiders at Phio Pharmaceuticals Corp. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | Phio Pharmaceuticals Corp. | Ronald Todd Plott director | $10k 10,000 shares | +31% | |
| 38Weak | Phio Pharmaceuticals Corp. | Patricia A Bradford director | $6,583 6,500 shares | +11% | |
| 35Weak | Phio Pharmaceuticals Corp. | Robert J Bitterman Chairman, Pres. & CEO | $2,058 2,000 shares | +1% | |
| 36Weak | Phio Pharmaceuticals Corp. | Patricia A Bradford director | $12k 12,000 shares | +26% | |
| 39Weak | Phio Pharmaceuticals Corp. | Ronald Todd Plott director | $17k 15,000 shares | - | |
| 41Moderate | Phio Pharmaceuticals Corp. | Robert J Bitterman Chairman, Pres. & CEO | $11k 10,000 shares | +2% | |
| 33Weak | PHIObuy Phio Pharmaceuticals Corp. | Robert J Bitterman Chairman, Pres. & CEO | $9,900 10,000 shares | +2% | |
| 48Moderate | PHIObuy Phio Pharmaceuticals Corp. | Robert J Bitterman Chairman, Pres. & CEO | $5,150 5,000 shares | +2% | |
| 48Moderate | PHIObuy Phio Pharmaceuticals Corp. | Robert J Bitterman Chairman, Pres. & CEO | $5,100 5,000 shares | +2% | |
| 38Weak | PHIObuy Phio Pharmaceuticals Corp. | Robert J Bitterman Chairman, Pres. & CEO | $5,700 5,000 shares | +2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.